Researchers at Ireland's Waterford Institute of Technology have been awarded nearly $1 million to test and develop transdermal medications for conditions such as non-melanoma skin cancer.
Hanmi Pharmaceutical has signed a licensing agreement for Kinex Pharmaceuticals to develop its Orascovery pump inhibitor for gastrointestinal treatments in India.
Investigators have begun testing new drugs that can specifically hunt down and eliminate senescent cells in mice, opening the door to what they say could be a new class of therapeutics that promise to one day slow down the human aging process.
Canadian CRO conglomerate Altasciences struck a deal with preclinical researcher ITR Laboratories, joining forces to create a discovery-to-development offering for drugmakers.
Want Sovaldi (sofosbuvir), the hepatitis C drug selling in the United States for $1,000 per pill, for just $10 a pill? Go to Bangladesh or some other country where the drug is about to be produced and sold free of the control of Sovaldi's owner, Gilead Sciences.
Biotech companies got a boost in Japan on Friday as it was announced that SanBio will be listed publicly on the Tokyo Stock Exchange beginning April 8.
Japan's Asahi Kasei Pharma and U.K.-based Vernalis reached a second milestone on an undisclosed target for rheumatoid arthritis and other autoimmune diseases, which triggered a £500,000 payment to the British company.
Navidea Biopharmaceuticals is teaming up with European specialty pharma company Norgine to commercialize its Lymphoseek cancer diagnostic aid in Europe, looking to make a market splash as it drives international growth.
Hutchison China MediTech eyes first modern drug approval in China next year with Eli Lilly candidate
Hutchison China MediTech, based in Hong Kong, expects to file for its first drug approval next year for what it said would be the first modern drug developed in China since artemisinin was developed in the 1970s to treat malaria.
Denovo Biopharma will conduct clinical trials in China for its exclusively licensed pomaglumetad methionil, a late-stage neuroscience drug licensed from Eli Lilly.